Abstract: A drug dosage form is provided in the form of a solid tablet which is greater than 50% by weight the local anesthetic agent. The local anesthetic agent may be selected from the group consisting of an aminoamide, an aminoester, and a combination thereof. The drug tablet may be in the form of a mini-tablet which is greater than 70 wt % drug, with the balance being excipient. For example, the anesthetic agent may include lidocaine, in a salt or base form, combined with binder and lubricant excipients. Implantable drug delivery devices including the tablets are also provided, e.g., one or more of the drug tablets may be contained in a biocompatible housing. The drug tablets may be substantially cylindrical with flat end faces, and the device may have from 10 to 100 drug tablets aligned in the housing with the flat end faces of adjacent tablets abutting one another.
Type:
Grant
Filed:
June 21, 2021
Date of Patent:
December 19, 2023
Assignee:
TARIS Biomedical LLC
Inventors:
Karen Danielle Daniel, Burleigh M. Hutchins, III, Cheryl Larrivee-Elkins, Heejin Lee
Abstract: Formulated and/or co-formulated nanocarriers (e.g., LNPs and/or SLNPs) comprising PD-1 Prodrugs and methods of making the nanocarriers are disclosed herein. The PD-1 Prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit PD-1-L1/L2. The PD-1 Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
Type:
Grant
Filed:
September 10, 2021
Date of Patent:
December 5, 2023
Assignee:
Nammi Therapeutics, Inc.
Inventors:
David Stover, Dhruba Bharali, Bruce A Hay, Tahmineh Safaie
Abstract: A multi-layer article including a first non-active state and a second active state, the multi-layer article comprising an outer layer having a first side and a second side, an inner layer adjacent to at least a portion of the outer layer and including a volatile material, and an upper layer including a first side and a second side, the first side of the upper layer being adjacent to at least a portion of the inner layer. The multi-layer article is folded upon itself in the first non-active state so that at least a first portion of the second side of the upper layer is disposed on a top of a second portion of the second side of the upper layer, and the first portion and the second portion of the upper layer are heat sealed in the non-active state.
Abstract: An anti-cancer agent is provided comprising a tumour homing peptide having, or having been modified to present, two cysteine residues, with an arsenic atom between, such that the tumour homing peptide cyclises to give an arsenic-containing anti-cancer agent. This allows for selection of an appropriate tumour homing peptide for treatment of a given cancer whereby the subsequent agent provides for a more targeted delivery of arsenic to the tumour microenvironment.
Type:
Grant
Filed:
October 17, 2018
Date of Patent:
November 21, 2023
Assignee:
University of Wollongong
Inventors:
Carolyn Therese Dillon, Judith Anne Carrall
Abstract: A water-in-silicone cosmetic composition in the form of an emulsion. The cosmetic composition comprises an aqueous phase and a silicone phase. The aqueous phase comprises a hydrating agent from about 1% to about 40% by weight based on the total weight of the composition. The silicone phase having about 18% to about 40% of silicone-containing compounds by weight based on the total weight of the composition, comprises at least one silicone polymer; a film former from about 0.01% to about 4% by weight based on the total weight of the composition; at least one emulsifying crosslinked siloxane elastomer; at least one co-emulsifier from about 0.1% to about 3% by weight based on the total weight of the composition; and wherein the cosmetic composition has a unique occlusive texture that provides low friction and high glide.
Type:
Grant
Filed:
June 7, 2018
Date of Patent:
November 7, 2023
Assignee:
L'OREAL
Inventors:
Paul Pierre Bonvallet, Susan Halpern Chirch, Zachary Maron, Lilian Lam Josephson
Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Type:
Grant
Filed:
October 6, 2020
Date of Patent:
November 7, 2023
Assignee:
Acceleron Pharma Inc.
Inventors:
Ravindra Kumar, Rajasekhar Naga Venkata Sai Suragani, John Knopf
Abstract: A method of preparing iron oxide nanoparticles using an herbal mixture comprising Capparis spinosa, Cichorium intybus, Solanum nigrum, Cassia occidentalis, Terminalia arjuna, Achillea millefolium, and Tamarix gallica. The method produces crystalline ?-Fe2O3 nanoparticles which are superparamagnetic. The iron oxide nanoparticles are used in a method of killing or inhibiting the growth of a bacteria and/or fungus, particularly in the form of a biofilm. The nanoparticles are also used in a method of treating colon cancer.
Abstract: The systems and methods disclosed herein relate generally to microbubble-assisted delivery of a therapeutic agent, such as a chemotherapeutic agent, to cells or tissue of interest, either in vitro or in vivo, that can be activated by directed ultrasound irradiation. For example, hydrophobic sonosensitizers can be incorporated in microbubble complexes to provide improved sonodynamic therapies.
Type:
Grant
Filed:
September 5, 2018
Date of Patent:
October 24, 2023
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education
Inventors:
Xucai Chen, Qin Bin, Villanueva Flordeliza
Abstract: A spiky metal organic framework is provided in the present disclosure. The spiky metal organic framework is formed by a coordination reaction between at least one metal ion and an organic ligand, and includes a body and a plurality of spike-like structures. The body is a spherical shape, and a particle size of the body is 1 ?m to 3 ?m. The spike-like structures are distributed on a surface of the body, a diameter of each spike-like structure is 15 nm to 35 nm, and a length of each spike-like structure is 250 nm to 400 nm.
Abstract: The present invention is directed to reduced and highly oxidized polysaccharides, such as alginates, that are useful for encapsulating therapeutic or diagnostic agents, or lipid based nanoparticles, e.g., liposomes or virosomes, encapsulating therapeutic or diagnostic agents, prior to their delivery into a subject, as well as methods for making and using them.
Type:
Grant
Filed:
August 13, 2020
Date of Patent:
October 3, 2023
Assignee:
President and Fellows of Harvard College
Inventors:
David J. Mooney, Alexander Stafford, Rajiv Desai, Kathleen Martinick
Abstract: An application of a transgenic stem cell-derived exosome in preparing a medicament or whitening cosmetic is provided. In the present disclosure, miR-27b-3p is transfected into an epidermal stem cell, and a transgenic stem cell-derived exosome is harvested. It is experimentally verified that the exosome can inhibit the expression of PIK3R3 protein in melanocytes and the proliferation and migration of melanocytes; and safety experiments further demonstrate the safety of the exosome. Therefore, corresponding medicaments or cosmetics prepared from the exosome have excellent medicinal and cosmetic application prospects.
Type:
Grant
Filed:
March 22, 2021
Date of Patent:
September 19, 2023
Assignee:
GUANGDONG CELL BIOTECHNOLOGY CO., LTD.
Inventors:
Xinyi Shi, Taihua Wang, Fei Peng, Jing Li
Abstract: Provided are multi-arm polymer conjugates of Toll-Like Receptor (“TLR”) agonists such as TLR 7/8 agonists, as well as related compositions, and methods of making and using such conjugates. Exemplary conjugates are encompassed by Formula I: (I) or a pharmaceutically acceptable salt form thereof, where R, taken together with each Q, is a residue of a polyol, polythiol, or polyamine bearing from 3 to about 50 hydroxyl, thiol, or amino groups; each Q is a linker selected from oxygen, sulfur and —NH; each POLY is independently a water-soluble, non-peptidic polymer; each Xr is independently a linkage-containing spacer moiety; q is a positive integer from 3 to about 50; and each TLR 7/8 AG is a Toll-like receptor 7/8 agonist. Also provided is a method of administering to a patient having cancer (a) an IL-2R?-activating amount of a long-acting, IL-2R?-selective agonist; and (b) a Toll-like receptor agonist such as a conjugate as described above, as well as related compositions, kits and methods.
Type:
Grant
Filed:
January 10, 2018
Date of Patent:
September 5, 2023
Assignee:
Nektar Therapeutics
Inventors:
Zhongxu Ren, Neel K. Anand, Haiying Cai, Bo-Liang Deng, Bhalchandra V. Joshi, Jonathan Zalevsky, Takahiro Miyazaki, Saul Kivimae
Abstract: A method of preparing iron oxide nanoparticles using an herbal mixture comprising Capparis spinosa, Cichorium intybus, Solanum nigrum, Cassia occidentalis, Terminalia arjuna, Achillea millefolium, and Tamarix gallica. The method produces crystalline ?-Fe2O3 nanoparticles which are superparamagnetic. The iron oxide nanoparticles are used in a method of killing or inhibiting the growth of a bacteria and/or fungus, particularly in the form of a biofilm. The nanoparticles are also used in a method of treating colon cancer.
Abstract: The invention pertains to a method for temporarily conferring advantageous cancer cell phenotypes, such as a higher proliferation rate, resistance to apoptosis and cell death, and resistance to endogenous factors that inhibit cell growth, on non-cancer cells that help repair and regenerate damaged tissues.
Type:
Grant
Filed:
April 22, 2019
Date of Patent:
September 5, 2023
Assignees:
National Guard Health Affairs, King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center
Abstract: The disclosure relates generally to alpha polyglutamated pralatrexate, formulations containing liposomes filled with alpha polyglutamated pralatrexate, methods of making the alpha polyglutamated pralatrexate and liposome containing formulations, and methods of using polyglutamated alpha polyglutamated pralatrexate and liposome containing formulations to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).
Abstract: The present invention relates to cancer immunotherapy, in particular to sequence variants of tumor-related antigenic epitope sequences. Namely, the present invention provides a method for identification of microbiota sequence variants of tumor-related antigenic epitope sequences. Such microbiota sequence variants are useful for the preparation of anticancer medicaments, since they differ from self-antigens and, thus, they may elicit a strong immune response. Accordingly, medicaments comprising microbiota sequence variants, methods of preparing such medicaments and uses of such medicaments are provided.
Abstract: Provided herein is a pharmaceutical composition comprising an effective amount of cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Lys-OH (LS301), cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Tyr-OH (LS838) or pharmaceutically acceptable salts thereof, wherein each amino acid residue is independently in a D or L configuration; a divalent metal ion; and a pharmaceutically acceptable carrier. Further provided are lyophilized products comprising a dye-conjugate and m methods for identifying compromised and for binding phosphorylated annexin A2 (pANXA2) protein in a biological sample using a composition described herein.
Type:
Grant
Filed:
December 11, 2020
Date of Patent:
August 1, 2023
Assignee:
WASHINGTON UNIVERSITY
Inventors:
Samuel Achilefu, Rui Tang, Duanwen Shen, Avik Som, Baogang Xu, Gail Sudlow, Christopher Egbulefu, Partha Karmakar, Kexian Liang
Abstract: Conformationally restricted cyanine fluorophores, as well as methods of making and using the compounds, are described. The conformationally restricted cyanine fluorophores have a chemical structure according to Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof: wherein A is and wherein each “*” designates an attachment point of A.
Type:
Grant
Filed:
March 10, 2021
Date of Patent:
July 25, 2023
Assignee:
The USA, as represented by the Secretary, Department of Health and Human Services
Abstract: This application relates to nanoparticles, including nanoparticles derived from a plasma, and their use in the formation of conjugates. The nanoparticles can be stably conjugated to a wide variety of second species, forming conjugates which can be used, for example, in therapeutic, diagnostic and experimental methods.
Type:
Grant
Filed:
December 21, 2017
Date of Patent:
June 27, 2023
Assignee:
NANOMEDX, INC.
Inventors:
Miguel Angelo Correia Dos Santos, Elysse Filipe, Praveesuda Lorwattanapongsa, Marcela Bilek, Steven Garry Wise